| You are in:Home/Publications/Efcacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease | |
Dr. Ahmed Mahmoud Bendary :: Publications: |
|
| Title: | Efcacy and safety of combination therapy
Ezetimibe 10/rosuvastatin 40 in Egyptian
patients at very high risk of atherosclerotic
cardiovascular disease |
| Authors: | Mohamed Sobhy, Hala Mahfouz Badran, Mahmoud Hassanein, Samir Rafla, Tarek Zawawy, Amr Zaki, Mohamed Loutfi, Mohamed Sadaka, Sherif Ayad, Amr Kamal, Ahmed Mokhtar & ZEOS investigator group |
| Year: | 2025 |
| Keywords: | LDL-C reduction, ESC LDL-C targets, Hyperlipidemia, Rosuvastatin-Ezetimibe |
| Journal: | The Egyptian Heart Journal |
| Volume: | Not Available |
| Issue: | Not Available |
| Pages: | Not Available |
| Publisher: | Springer Nature |
| Local/International: | International |
| Paper Link: | |
| Full paper | Ahmed Mahmoud Bendary_TEHJ.pdf |
| Supplementary materials | Not Available |
| Abstract: |
Background Lipid-lowering therapies (LLT) are well-established in reducing cardiovascular complications and improving outcomes in patients with atherosclerotic cardiovascular disease (ASCVD). However, the efficacy of LLT varies across different ethnic and geographical populations, necessitating further investigation. Objectives To evaluate the real-world efficacy and safety of the combination therapy of Ezetimibe 10 mg/Rosuvastatin 40 mg in Egyptian patients at very high risk of ASCVD. Methods This multicenter, prospective, single-arm, open-label study enrolled adult patients with documented ASCVD or at very high-risk profiles. Lipid parameters, including total cholesterol (TC), LDL-C, HDL-C, non-HDL-C, and triglycerides, were measured at baseline, 6 weeks, and 12 weeks. The primary endpoint was the proportion of patients achieving the ESC LDL-C target ( |
